The compassion question

The videos opened the door.
The trials had to walk through it.

Some cannabis stories should not be mocked.

• A child stops convulsing.
• A father moves state.
• A mother crosses a border.
• A family breaks the law because the legal system has no answer left.
• A patient with Parkinson’s tremor appears calmer after using cannabis.
• A person who could not rest suddenly rests.

These moments matter.

• They matter even when they are not clinical trials.
• They matter even when the video is incomplete.
• They matter even when the mechanism is uncertain.
• They matter because suffering is evidence of need, even when it is not evidence of efficacy.

This is where cannabis education must be careful.

A video can open the heart.
It cannot close the scientific question.

In epilepsy, the story is no longer only anecdote. Purified cannabidiol, sold as Epidiolex in the United States and Epidyolex in parts of Europe, is an approved medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in patients from 1 year of age in the US label. That matters. It means one cannabis-derived compound crossed the line from desperate story to regulated medicine for specific severe epilepsies.

But the detail matters just as much.

This is not “cannabis cures epilepsy”.
It is not “any oil will do”.
It is not “THC for children”.
It is not “watch a video and copy the dose”.

It is a standardised, prescription cannabidiol medicine, studied in controlled trials, used for specific seizure disorders, with medical monitoring, interactions and side effects. NICE guidance in the UK separately addresses cannabidiol with clobazam for Lennox-Gastaut and Dravet syndromes, while wider cannabis-based medicinal products for severe treatment-resistant epilepsy remain an area where more research has been recommended.

That distinction protects the story from becoming marketing.

• Families were not wrong to be desperate.
• Parents were not wrong to notice change.
• Campaigners were not wrong to demand research.

But compassion does not remove the need for measurement. It creates the obligation to measure better.

The same caution applies to Parkinson’s disease.

Many people have seen videos of tremor changing after cannabis use. Some patients report improvements in sleep, pain, anxiety, stiffness or quality of life. Those reports should not be dismissed as nonsense. But the evidence is not as settled as the videos make it feel. The Parkinson’s Foundation states that cannabis is being studied, but there is no conclusive evidence that it helps Parkinson’s symptoms. Recent reviews describe possible benefits in some motor and non-motor symptoms, while still calling for larger, better-controlled trials.

This is the uncomfortable middle.

• Not fake.
• Not proven enough.
• Not irrelevant.
• Not a miracle.

That middle is exactly where serious cannabis education must learn to stand.

Because the emotional force of these cases is real. A father watching his child suffer does not need a lecture from someone who has never lived inside that room. A patient whose hands will not obey does not need sarcasm from the healthy. When people are desperate, compassion is not optional.

But desperation is also where bad products, false promises and careless advice become most dangerous.

• A child with severe epilepsy is not a wellness customer.
• A person with Parkinson’s is not a marketing demographic.
• A family in crisis is not a sales funnel.

This is why the language must stay clean.

Cannabis may help some people in some conditions, through some preparations, at some doses, under some circumstances. That sentence is less exciting than “cannabis heals”. It is also more honest.

The compassionate position is not to believe every claim.
The compassionate position is to care enough to ask better questions:

• What condition?
• What diagnosis?
• Which cannabinoid?
• Which product?
• Which dose?
• Which route?
• What other medicines?
• What interactions?
• What side effects?
• What outcome is being measured?
• Who is supervising?
• What happens if it fails?

For epilepsy, interactions matter. Cannabidiol can interact with other anti-seizure medicines, including clobazam, and liver-enzyme monitoring may be required with prescribed Epidiolex/Epidyolex. For Parkinson’s, THC-containing products may raise concerns around dizziness, cognition, balance, hallucinations or falls, especially in older or vulnerable patients.

So yes, the videos matter.

• They may show a real response.
• They may show a temporary effect.
• They may show a selected moment.
• They may omit failed attempts, adverse effects, tolerance, dose changes or other medicines.
• They may also be the reason a researcher, doctor, parent or policymaker finally pays attention.

The video is not the conclusion.
It is the beginning of responsibility.

Cannabis education should be able to hold both truths at once: the tears of the parent and the discipline of the trial. The living child and the labelled bottle. The shaking hand and the uncertainty of the evidence. The need for access and the need for protection.

Evidence is not prohibition.
Evidence is protection.

And compassion without evidence
can become another kind of risk.